Gemtuzumab Ozogamicin
Title: Gemtuzumab Ozogamicin
CAS Registry Number: 220578-59-6
Manufacturers' Codes: CDP-771; CMA-676
Trademarks: Mylotarg (Wyeth)
Literature References: Immunoconjugate of N-acetyl-g-calicheamicin with the humanized mouse monoclonal IgG4 k antibody, hP67.6, directed against the human CD33 antigen located on the surface of normal and leukemic myeloid cells, but not on normal hematopoietic stem cells. Designed to deliver antibody-targeted chemotherapy for treatment of acute myelocytic leukemia (AML). Prepn of conjugate: P. R. Hamann et al., EP 689845; eidem, US 5773001 (1996, 1998 both to Am. Cyanamid). In vitro antineoplastic activity: K. Naito et al., Leukemia 14, 1436 (2000). Clinical evaluation in AML: E. L. Sievers et al., Blood 93, 3678 (1999). Reviews of development and therapeutic potential: I. D. Bernstein, Leukemia 14, 474-475 (2000); I. Niculescu-Duvaz, Curr. Opin. Mol. Ther. 2, 691-696 (2000); of clinical experience: F. J. Giles, Expert Rev. Anticancer Ther. 2, 630-640 (2002).
Properties: Sensitive to light; protect from direct and indirect sunlight and unshielded fluorescent light.
Therap-Cat: Antineoplastic
Keywords: Antineoplastic; Monoclonal Antibodies.

Others monographs:
Calcium OxalateSpirit of Ammonia, AromaticOripavine4-Pregnene-20,21-diol-3,11-dione
o-Cresotic AcidQuebracho Colorado9,10-Dimethyl-1,2-benzanthraceneMagnesium Oxalate
EnoxaparinAllyl Ethyl Ether3-Amino-2-naphthoic Acid2,4,6-Trinitrobenzoic Acid
Streptomycin BNipecotic AcidHarmalolPotassium Persulfate
©2016 DrugLead US FDA&EMEA